Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. Summary
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  05/13 03:59:55 pm EDT
1.810 CAD   +9.70%
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
05/09/2022 05/10/2022 05/11/2022 05/12/2022 05/13/2022 Date
1.72(c) 1.64(c) 1.63(c) 1.65(c) 1.81(c) Last
221 986 83 655 51 277 233 968 105 201 Volume
-10.42% -4.65% -0.61% +1.23% +9.70% Change
More quotes
Estimated financial data (e)
Sales 2022 36,6 M 28,3 M 28,3 M
Net income 2022 -7,29 M -5,64 M -5,64 M
Net Debt 2022 - - -
P/E ratio 2022 -26,8x
Yield 2022 -
Sales 2023 54,4 M 42,0 M 42,0 M
Net income 2023 1,70 M 1,31 M 1,31 M
Net Debt 2023 - - -
P/E ratio 2023 60,3x
Yield 2023 -
Capitalization 196 M 152 M 152 M
Capi. / Sales 2022 5,36x
Capi. / Sales 2023 3,61x
Nbr of Employees 163
Free-Float 95,0%
More Financials
Company
OpSens Inc. provides fiber optic sensing technology. The Company operates through two segments: Medical and Industrial. The Medical segment focuses on physiological measurement, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications... 
Read more
More about the company
Ratings of Opsens Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about OPSENS INC.
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
04/13TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022
CI
04/13OPSENS : CEO Certification
PU
04/13OPSENS : CFO Certification
PU
04/13Opsens Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Februa..
CI
04/13OpSens Swings to Loss in Fiscal Q2 as Consolidated Sales Drop
MT
04/13OPSENS BRIEF : Net loss was $2.4 million in Q2 2022 compared with a net income of $41,000 ..
MT
04/13OPSENS BRIEF : Consolidated sales were $8.1 million in Q2 2022, compared with $8.8 million..
MT
04/13Opsens announces second quarter fiscal 2022 financial results
AQ
04/06Opsens to host second quarter fiscal year 2022 financial results conference call on wed..
AQ
03/14OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th t..
AQ
02/25OpSens Reports on Voting Results from its Annual Shareholders Meeting
AQ
02/09Opsens appoints brad davis as new chief commercial officer
AQ
More news
News in other languages on OPSENS INC.
04/26Opsens Inc. Annonce l'approbation de Santé Canada pour son nouveau fil-guide TAVR
04/13Opsens Inc. annonce ses résultats pour le deuxième trimestre et les six mois terminés l..
04/13OpSens subit une perte au deuxième trimestre de l'exercice financier alors que les vent..
02/09OpSens Inc. nomme Brad Davis au poste de chef de la direction commerciale
02/01OpSens Inc. annonce l'extension du contrat d'approvisionnement de 4 ans d'Abiomed jusqu..
More news
Analyst Recommendations on OPSENS INC.
More recommendations
Chart OPSENS INC.
Duration : Period :
Opsens Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPSENS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,81 CAD
Average target price 4,22 CAD
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Louis Laflamme President, Chief Executive Officer & Director
Robin Villeneuve Chief Financial Officer & Secretary
Alan W. Milinazzo Executive Chairman
Jean Lavigueur Independent Director
Denis L. Harrington Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OPSENS INC.-41.61%152
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652